These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 15090747)

  • 1. Co-administration of simvastatin and cytotoxic drugs is advantageous in myeloma cell lines.
    Drucker L; Afensiev F; Radnay J; Shapira H; Lishner M
    Anticancer Drugs; 2004 Jan; 15(1):79-84. PubMed ID: 15090747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microenvironment factors do not afford myeloma cell lines protection from simvastatin.
    Osadchy A; Drucker L; Radnay J; Shapira H; Lishner M
    Eur J Haematol; 2004 Sep; 73(3):183-90. PubMed ID: 15287916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simvastatin induces death of multiple myeloma cell lines.
    Gronich N; Drucker L; Shapiro H; Radnay J; Yarkoni S; Lishner M
    J Investig Med; 2004 Jul; 52(5):335-44. PubMed ID: 15551657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bcl-2 overexpression is associated with resistance to dexamethasone, but not melphalan, in multiple myeloma cells.
    Gazitt Y; Fey V; Thomas C; Alvarez R
    Int J Oncol; 1998 Aug; 13(2):397-405. PubMed ID: 9664139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro treatment with retinoids decreases bcl-2 protein expression and enhances dexamethasone-induced cytotoxicity and apoptosis in multiple myeloma cells.
    Tosi P; Pellacani A; Visani G; Ottaviani E; Ronconi S; Zamagni E; Benni M; Cavo M; Tura S
    Eur J Haematol; 1999 Mar; 62(3):143-8. PubMed ID: 10089890
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Terzi H; Altun A; Şencan M
    Indian J Med Res; 2019 Dec; 150(6):630-634. PubMed ID: 32048627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan.
    Trudel S; Stewart AK; Li Z; Shu Y; Liang SB; Trieu Y; Reece D; Paterson J; Wang D; Wen XY
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):621-9. PubMed ID: 17255285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The bisphosphonate zoledronic acid induces cytotoxicity in human myeloma cell lines with enhancing effects of dexamethasone and thalidomide.
    Ural AU; Yilmaz MI; Avcu F; Pekel A; Zerman M; Nevruz O; Sengul A; Yalcin A
    Int J Hematol; 2003 Dec; 78(5):443-9. PubMed ID: 14704038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma.
    Kaiser M; Lamottke B; Mieth M; Jensen MR; Quadt C; Garcia-Echeverria C; Atadja P; Heider U; von Metzler I; Türkmen S; Sezer O
    Eur J Haematol; 2010 Apr; 84(4):337-44. PubMed ID: 20028416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS-mutant multiple myeloma.
    Sriskandarajah P; De Haven Brandon A; MacLeod K; Carragher NO; Kirkin V; Kaiser M; Whittaker SR
    BMC Cancer; 2020 Mar; 20(1):269. PubMed ID: 32228485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitors of protein kinase C sensitise multiple myeloma cells to common genotoxic drugs.
    Baumann P; Armann J; Mandl-Weber S; Grün G; Oduncu F; Schmidmaier R
    Eur J Haematol; 2008 Jan; 80(1):37-45. PubMed ID: 18028419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of melphalan and dexamethasone in a human myeloma cell line.
    Fernberg JO; Lewensohn R; Skog S
    Anticancer Drugs; 1991 Dec; 2(6):565-70. PubMed ID: 1806033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of As2O3, dexamethasone and thalidomide on apoptosis and cytoplasmic [Ca2+] of myeloma cell line U266].
    Lin RF; Lu H; Liu P; Wang YR; Shen WY; Wu YJ; Zhang JF; Fei XM; Ge Z; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Dec; 15(6):1200-3. PubMed ID: 18088466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elucidating the beneficial effects of melphalan, adriamycin, and corticoids in combination with bortezomib against multiple myeloma in vitro.
    Schäfer J; Burhenne J; Weiss J; Theile D
    Naunyn Schmiedebergs Arch Pharmacol; 2019 Apr; 392(4):461-466. PubMed ID: 30554340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan.
    Rowley M; Liu P; Van Ness B
    Blood; 2000 Nov; 96(9):3175-80. PubMed ID: 11050000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of the mevalonate pathway potentiates the effects of lenalidomide in myeloma.
    van der Spek E; Bloem AC; Lokhorst HM; van Kessel B; Bogers-Boer L; van de Donk NW
    Leuk Res; 2009 Jan; 33(1):100-8. PubMed ID: 18621417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxic activities of hydroxyethyl piperazine-based σ receptor ligands on cancer cells alone and in combination with melphalan, PB28 and haloperidol.
    Korpis K; Weber F; Wünsch B; Bednarski PJ
    Pharmazie; 2014 Dec; 69(12):917-22. PubMed ID: 25951666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simvastatin suppresses head and neck squamous cell carcinoma ex vivo and enhances the cytostatic effects of chemotherapeutics.
    Stoehr M; Mozet C; Boehm A; Aigner A; Dietz A; Wichmann G
    Cancer Chemother Pharmacol; 2014 Apr; 73(4):827-37. PubMed ID: 24562588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
    Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
    Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dexamethasone plus retinoids decrease IL-6/IL-6 receptor and induce apoptosis in myeloma cells.
    Smith MR; Xie T; Joshi I; Schilder RJ
    Br J Haematol; 1998 Sep; 102(4):1090-7. PubMed ID: 9734662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.